Cooperation between transmissible gastroenteritis coronavirus (TGEV) structural proteins in the in vitro induction of virus-specific antibodies.
Following infection of haplotype defined NIH-miniswine with virulent transmissible gastroenteritis coronavirus (TGEV), isolated mesenteric lymph node CD4+ T-cells mounted a specific proliferative response against infectious or inactivated purified virus in secondary in vitro stimulation. A specific, dose-dependent response to the three major recombinant viral proteins: spike (S), membrane (M), and nucleoprotein (N), purified by affinity chromatography, was characterized. Induction of in vitro antibody synthesis was analyzed. The purified recombinant viral proteins induced the in vitro synthesis of neutralizing TGEV-specific antibodies when porcine TGEV-immune cells were stimulated with each of the combinations made with two of the major structural proteins: S + N, S + M, and to a minor extent with M + N, but not by the individual proteins. S-protein was dissociated from purified virus using NP-40 detergent and then micellar S-protein oligomers (S-rosettes) were formed by removing the detergent. These occurred preferentially by the association of more than 10 S-protein trimmers. These S-rosettes in collaboration with either N or M-proteins elicited TGEV-specific antibodies with titers up to 84 and 60%, respectively, of those induced by the whole virus. N-protein could be partially substituted by a 15-mer peptide that represents a T helper epitope previously identified in N-protein (Antón et al. (1995)). These results indicate that the induction of high levels of TGEV-specific antibodies requires stimulation by at least two viral proteins, and that optimum responses are induced by a combination of S-rosettes and the nucleoprotein.
Antón
I M
IM
CSIC, Department of Molecular and Cell Biology, Madrid, Spain.
González
S
S
Bullido
M J
MJ
Corsín
M
M
Risco
C
C
Langeveld
J P
JP
Enjuanes
L
L
D000818:Animals; D019138:Antibodies, Blocking / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000914:Antibodies, Viral / Q000096:biosynthesis*; D000954:Antigens, Surface / Q000276:immunology; D002460:Cell Line; D004848:Epithelium; D006239:Haplotypes / Q000276:immunology; D008213:Lymphocyte Activation; D008297:Male; D008823:Micelles; D011994:Recombinant Proteins / Q000276:immunology / Q000302:isolation & purification / Q000494:pharmacology; D013045:Species Specificity; D013552:Swine; D013556:Swine, Miniature; D013601:T-Lymphocytes / Q000276:immunology; D013737:Testis; D005760:Transmissible gastroenteritis virus / Q000737:chemistry* / Q000235:genetics / Q000276:immunology*; D014764:Viral Proteins / Q000302:isolation & purification; D015678:Viral Structural Proteins / Q000235:genetics / Q000276:immunology* / Q000502:physiology*
D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000954:Antigens, Surface; D008823:Micelles; D011994:Recombinant Proteins; D014764:Viral Proteins; D015678:Viral Structural Proteins; C064484:spike protein S, Transmissible gastroenteritis virus